'Authorized Biosimilars' Cannot Use 351(k) Pathway

FDA Concludes Reference Product Must Be Another Biological Product

 
• By Sue Sutter
  
Calendar_23_March
US FDA is finalizing preparations for the regulatory transition that will take place on 23 March • Source: Shutterstock

More from Biosimilars

More from Products